Avid Radiopharmaceuticals, Inc. is developing novel diagnostic imaging agents to enable earlier and more accurate diagnosis, treatment selection and therapeutic monitoring of major medical disorders. The company is a pioneer in the development of molecular imaging agents for Alzheimer’s disease and other neurological disorders and is developing products for imaging with both positron emission tomography (PET) and single photon computed tomography (SPECT). The company has a collaboration in place with Bayer Schering Pharma AG to develop its first PET molecular imaging agent for AD. In addition, Avid is currently conducting clinical studies on a pipeline of next generation PET and SPECT agents. The company also has collaborative relationships with leading molecular imaging researchers at the University of Pennsylvania and the University of Michigan.
Collectively, AD, PD and DLB represent nearly 80% of the memory disorders that affect patients in the United States. According to a recent report issued by the World Health Organization entitled “Neurological disorders: Public Health Challenges,” nearly one billion people worldwide are affected by neurological disorders. An estimated 6.8 million people die every year as a result of neurological disorders. As the global population ages, there is an increasing demand for innovative, accurate solutions to diagnose these diseases. Avid’s vision is to develop novel diagnostic imaging agents to enable earlier and more accurate diagnosis, treatment selection and therapeutic monitoring for these significant medical disorders.
Avid is a leader in the development of radiopharmaceutical imaging agents for CNS diseases, which is a fast-growing, underserved market. These agents have the potential to revolutionize early diagnosis and monitoring of neurodegenerative diseases and may become major growth drivers in the radiopharmaceutical business. Avid benefits in its efforts from a team of individuals who have significant experience in product development in both neurology and nuclear medicine.
Website:
www.avidrp.com
Safeguard Partner Company since 2007
